Novel targets and future strategies for acute cardioprotection: Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart

Archive ouverte

Hausenloy, D. J. | Garcia-Dorado, D. | Botker, H. E. | Davidson, S. M. | Downey, J. | Engel, F. B. | Jennings, R. | Lecour, S. | Leor, J. | Madonna, R. | Ovize, Michel | Perrino, C. | Prunier, F. | Schulz, R. | Sluijter, J. P. G. | van Laake, L. W. | Vinten-Johansen, J. | Yellon, D. M. | Ytrehus, K. | Heusch, G. | Ferdinandy, P.

Edité par CCSD ; Oxford University Press (OUP) -

International audience. Ischaemic heart disease and the heart failure that often results, remain the leading causes of death and disability in Europe and worldwide. As such, in order to prevent heart failure and improve clinical outcomes in patients presenting with an acute ST-segment elevation myocardial infarction and patients undergoing coronary artery bypass graft surgery, novel therapies are required to protect the heart against the detrimental effects of acute ischaemia/reperfusion injury (IRI). During the last three decades, a wide variety of ischaemic conditioning strategies and pharmacological treatments have been tested in the clinic-however, their translation from experimental to clinical studies for improving patient outcomes has been both challenging and disappointing. Therefore, in this Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart, we critically analyse the current state of ischaemic conditioning in both the experimental and clinical settings, provide recommendations for improving its translation into the clinical setting, and highlight novel therapeutic targets and new treatment strategies for reducing acute myocardial IRI.

Consulter en ligne

Suggestions

Du même auteur

Melatonin as a cardioprotective therapy following ST-segment elevation myocardial infarction: is it really promising? Reply

Archive ouverte | Hausenloy, D. J. | CCSD

International audience

ESC Working Group Cellular Biology of the Heart: Position Paper: improving the preclinical assessment of novel cardioprotective therapies

Archive ouverte | Lecour, S. | CCSD

International audience. Ischaemic heart disease (IHD) remains the leading cause of death and disability worldwide. As a result, novel therapies are still needed to protect the heart from the detrimental effects of a...

Ischaemic conditioning and targeting reperfusion injury: a 30 year voyage of discovery

Archive ouverte | Hausenloy, D. J. | CCSD

International audience. To commemorate the auspicious occasion of the 30th anniversary of IPC, leading pioneers in the field of cardioprotection gathered in Barcelona in May 2016 to review and discuss the history of...

Chargement des enrichissements...